4-fluoro-N-(((6S,12R,13R)-15-((2S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-6,13-dimethyl-16-oxo-6,7,8,9,10,12,13,14,15,16-decahydropyrazino[2,3-b][1,9,5]dioxaazacyclotetradecin-12-yl)methyl)-N-methylbenzenesulfonamide | 1403478-59-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 4-fluoro-N-(((6S,12R,13R)-15-((2S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-6,13-dimethyl-16-oxo-6,7,8,9,10,12,13,14,15,16-decahydropyrazino[2,3-b][1,9,5]dioxaazacyclotetradecin-12-yl)methyl)-N-methylbenzenesulfonamide
• 英文别名: 4-fluoro-N-(((6S,12R,13R)-15-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-6,13-dimethyl-16-oxo-6,7,8,9,10,12,13,14,15,16-decahydropyrazino[2,3-b][1,9,5]dioxaazacyclotetradecin-12-yl)methyl)-N-methylbenzenesulfonamide；4-fluoro-N-[[(3S,9R,10R)-12-[(2S)-1-[(4-methoxyphenyl)methoxy]propan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12,15,18-triazabicyclo[12.4.0]octadeca-1(18),14,16-trien-9-yl]methyl]-N-methylbenzenesulfonamide
• CAS: 1403478-59-0
• 化学式: C₃₄H₄₅FN₄O₇S
• 分子量: 672.818
• InChiKey: UDKDJFWQMRARJO-OLHJXYGRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  47
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  129
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  N-((2R,3R)-2-((tert-butyldimethylsilyl)oxy)-4-(((2S)-1-((4-methoxybenzyl)oxy)propan-2-yl)amino)-3-methylbutyl)-4-fluoro-N-methylbenzenesulfonamide 在 Wilkinson's catalyst 、 Hoveyda-Grubbs catalyst second generation 、 四丁基氟化铵 、 氢气 、 双(2-氧代-3-恶唑烷基)次磷酰氯 、 sodium hydride 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 、 叔丁醇 为溶剂， 反应 77.5h， 生成 4-fluoro-N-(((6S,12R,13R)-15-((2S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-6,13-dimethyl-16-oxo-6,7,8,9,10,12,13,14,15,16-decahydropyrazino[2,3-b][1,9,5]dioxaazacyclotetradecin-12-yl)methyl)-N-methylbenzenesulfonamide
  参考文献：
  名称：

  Diversity-Oriented Synthesis-Facilitated Medicinal Chemistry: Toward the Development of Novel Antimalarial Agents

  摘要：

  Here, we describe medicinal chemistry that was accelerated by a diversity-oriented synthesis (DOS) pathway, and in vivo studies of our previously reported macrocyclic antimalarial agent that derived from the synthetic pathway. Structure-activity relationships that focused on both appendage and skeletal features yielded a nanomolar inhibitor of P. falciparum asexual blood-stage growth with improved solubility and microsomal stability and reduced hERG binding. The build/couple/pair (B/C/P) synthetic strategy, used in the preparation of the original screening library, facilitated medicinal chemistry optimization of the antimalarial lead.

  DOI：

  10.1021/jm500994n

文献信息

• [EN] MACROLACTAM COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA<br/>[FR] COMPOSÉS MACROLACTAMES ET MÉTHODES DE TRAITEMENT DU PALUDISME
  申请人：BROAD INST INC

  公开号：WO2012142457A3

  公开（公告）日：2013-02-07
• Diversity-Oriented Synthesis-Facilitated Medicinal Chemistry: Toward the Development of Novel Antimalarial Agents
  作者：Eamon Comer、Jennifer A. Beaudoin、Nobutaka Kato、Mark E. Fitzgerald、Richard W. Heidebrecht、Maurice duPont Lee、Daniela Masi、Marion Mercier、Carol Mulrooney、Giovanni Muncipinto、Ann Rowley、Keila Crespo-Llado、Adelfa E. Serrano、Amanda K. Lukens、Roger C. Wiegand、Dyann F. Wirth、Michelle A. Palmer、Michael A. Foley、Benito Munoz、Christina A. Scherer、Jeremy R. Duvall、Stuart L. Schreiber

  DOI：10.1021/jm500994n

  日期：2014.10.23

  Here, we describe medicinal chemistry that was accelerated by a diversity-oriented synthesis (DOS) pathway, and in vivo studies of our previously reported macrocyclic antimalarial agent that derived from the synthetic pathway. Structure-activity relationships that focused on both appendage and skeletal features yielded a nanomolar inhibitor of P. falciparum asexual blood-stage growth with improved solubility and microsomal stability and reduced hERG binding. The build/couple/pair (B/C/P) synthetic strategy, used in the preparation of the original screening library, facilitated medicinal chemistry optimization of the antimalarial lead.